The market opened in the red on July 14, 2020, overall volumes in futures & options currently stand at 1,88,70,614 crore contracts with a turnover of Rs. 11,67,812.51 crore.

The market opened in the red on July 14, 2020, overall volumes in futures & options currently stand at 1,88,70,614 crore contracts with a turnover of Rs. 11,67,812.51 crore.

To encourage listing of startups and also to develop a ‘high investor depth’ platform for such companies, Bombay Stock Exchange (BSE) announced that they have signed a pact with IIT Alumni Council.

The company’s revenue and profitability are likely to be impacted even more. In Q1FY21 (April-June), volumes and revenues seem to take a hit as the operations were partially shut in April 2020 and gradually ramped up during May 2020 and June 2020. However, recovery is likely to be expected during Q3FY21E and Q4FY21E.

On Monday, the stock has given a downward sloping trendline breakout on the daily timeframe, formed by connecting swing highs from May 2020. The breakout was supported by robust volumes.

The wait continues for the bulls to cross above the 200-DMA that acted as a resistance, as markets failed to capitalize on it. This was despite a strong start in the last trading session. On Tuesday, early trends in SGX Nifty suggests that Indian markets are expected to open in red, mimicking the weak global cues.

Our advice to traders is to initiate a long position only if Nifty sustains above the 200-DMA. While, on the downside, a close below the previous bar’s low will be the first sign of weakness.  Stocks in news: Reliance Industries, Cipla, Adani Ports, Godrej Industries.

Domestic benchmark indices closed in green on Monday after a volatile trading session with Sensex gaining by 99.36 points or 0.27 per cent at 36,693.69 while Nifty rose by 47.15 points or by 0.44 per cent to settle at 10,815.20.

The new price of the drug is Rs 75 per tab, which has been reduced by 27 per cent as against the earlier price of Rs 103 per tab.

In a landmark move, Indian pharma giant, Biocon announced that it has received approval from Drug Controller General of India (DCGI) to market Itolizumab injection in the strengths of 25 mg/5 ml for severe COVID-19 patients.